STERIS plc (STE)

In May 2025, STERIS stock increased by 8.25% after surpassing Wall Street forecasts for its Q4 adjusted earnings per share and revenue, leading Morgan Stanley to increase its price target on STERIS shares. In July 2025, STERIS announced an increase in its quarterly interim dividend to $0.63 per share. In August 2025, the company reported total revenue up 9% year-over-year and a non-GAAP profit of $2.34 per share, also announcing a Chief Financial Officer transition. In October 2025, STERIS announced it would host a conference call on November 6, 2025, to discuss its fiscal 2026 second-quarter results.

While specific overall demand seasonality for all STERIS products and services is not explicitly detailed, there is an indication of seasonality within its bioprocessing demand. Bioprocessing demand seemed to have stabilized by the fourth quarter of fiscal 2024, and a return to meaningful bioprocessing growth is not expected until the second half of fiscal 2025. The company's Healthcare segment, however, consistently outperformed in fiscal 2024 with double-digit organic revenue growth.

STERIS Plc is a global leader in infection prevention and procedural products and services, primarily serving the healthcare, pharmaceutical, and medical device industries. The company provides solutions that support patient care with an emphasis on infection prevention. STERIS's major products and services include capital equipment such as surgical tables, sterilizers, and consumable products such as gastrointestinal endoscopy accessories. The company also provides a range of services, such as microbial reduction in medical devices, equipment installation and maintenance, and off-site reprocessing. STERIS is also a global leader in contract sterilization services.

STERIS Plc has a significant global presence, with operations in over 100 countries. Its legal headquarters are in Dublin, Ireland, while its operational headquarters are in Mentor, Ohio, U.S. The company maintains a robust network of manufacturing facilities, sales offices, service centers, and research and development sites across North America, Europe, Asia-Pacific, and Latin America. The United States accounts for a substantial portion of its net sales, approximately 73%.

STERIS Plc's reputation has been impacted by ongoing litigation related to claims of personal injury due to ethylene oxide emissions from a sterilization facility. A jury trial involving its subsidiary, Isomedix Operations, Inc., ended in a mistrial, prolonging the legal proceedings. STERIS has stated its commitment to defending against these allegations and emphasizes its investment in rigorous best practices to meet or exceed environmental standards.

Institutional investors hold a significant portion of STERIS Plc's shares, ranging from approximately 79.77% to 94.69%. Major institutional shareholders include Vanguard Group Inc., BlackRock Inc., and Massachusetts Financial Services Co. Individual investors account for a smaller percentage, around 0.33%.